
Developing a NET Cell Line
NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,
Make a gift before the end of the year to drive research breakthroughs in 2026.

NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,

New grants to explore CAR-T, PRRT, a vaccine for NETs and other innovative approaches.

Early Research on Targeting Single Cancer Cells to Prevent Metastasis Despite the effectiveness of Peptide Receptor Radionuclide Therapy (PRRT) to prolong survival of those with

The Neuroendocrine Tumor Research Foundation (NETRF) gratefully received a $35,000 donation for NET research from the CarGurus Charitable Giving Fund. NETRF was nominated by a

Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD, Assistant Professor of Surgical Oncology at the University of Alabama

We are proud to welcome Brendan P. Foley, Jr. as the newest member of the NET Research Foundation Board of Directors. Brendan has been elected

NETRF has launched a $10 million fundraising campaign, the largest of its kind in our history. Every gift we receive will be MATCHED, doubling our

NET Survivor Finds Hope and Inspiration That’s it—my number is up, Dave McCoy thought when he learned he had neuroendocrine cancer in 2008. A cancer, he

Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear

We are saddened to hear of the passing of Aretha Franklin, the Queen of Soul, who died of a pancreatic neuroendocrine tumor (pNET). She was